Healthcare utilization and costs among relapsed or refractory multiple myeloma patients on carfilzomib or pomalidomide as monotherapy or in combination with dexamethasone

Nav

General Info

Geography

United States of America (USA)

Time period covered

01/2006 - 12/2014

Data type

Scientific literature

Keywords

Chemotherapy, Health care costs, Multiple myeloma

Citation

Authors

Hagiwara M, Panjabi S, Sharma A, Delea TE

Journal

J Med Econ

Volume

Issue

Pages

818-829

Publication year

2019

Suggested citation

Hagiwara M, Panjabi S, Sharma A, Delea TE. Healthcare utilization and costs among relapsed or refractory multiple myeloma patients on carfilzomib or pomalidomide as monotherapy or in combination with dexamethasone. J Med Econ. 2019; 22(8): 818-829.

DOI

10.1080/13696998.2019.1614932

PMID

31046501

GHDx Entry last modified on: Mar 19, 2021

Header sites

Search form

Main menu

Healthcare utilization and costs among relapsed or refractory multiple myeloma patients on carfilzomib or pomalidomide as monotherapy or in combination with dexamethasone

Nav